Pay in 4 interest-free payments of $5.82 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
Main human AOD-9604 treatment timelines Study METAOD004 Participants 36 Route Oral Treatment length 7 days Dose range 9, 27, or 54 mg/day Main lesson Short safety and tolerability study Study METAOD005 Participants 300 Route Oral Treatment length 12 weeks Dose range 1 to 30 mg/day Main lesson Earlier weight-loss trial with a non-linear dose response Study METAOD006 Participants 502 randomized Route Oral Treatment length 24 weeks Dose range 0.25, 0.5, or 1 mg/day Main lesson Primary weight-loss goal was not met The oral milligram doses in these trials cannot be converted into subcutaneous microgram doses
IGF-1 (Somatomedin C): the primary marker of GH activity
Understanding these options helps you choose the right product for your specific goals
Follow the advice of your health professional
It is not about replacing training, food, or recovery fundamentals
